<DOC>
	<DOCNO>NCT01845064</DOCNO>
	<brief_summary>DM199 ( recombinant human tissue kallikrein-1 ) new investigational compound may eventually use treatment Diabetes Mellitus Type 2 . This first time compound give human . The purpose study investigate extent DM199 safe tolerate . Further , investigated quickly extent DM99 absorb eliminate body ( call pharmacokinetics ) . In addition , effect compound body investigate ( call pharmacodynamics ) . This study intend improve anyone 's health , necessary development DM199 . The study consist 4 part . Each part ( A , B , C D ) consist one several period . The research conduct healthy male female volunteer ( Part A C ) male female type 2 diabetes mellitus patient ( Part B D ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness DM199 Healthy Subjects Type 2 Diabetes Patients</brief_title>
	<detailed_description>DM199 ( recombinant human tissue kallikrein-1 ) develop new biological treatment type 2 diabetes mellitus . This first-in-human study DM199 4-part , single center study healthy subject type 2 diabetes mellitus patient . Part A randomized , double-blinded , placebo-controlled , single ascend dose ( SAD ) study healthy male and/or female subject . Subjects receive DM199 placebo subcutaneously ( sc ) . Part B randomized , partially double-blinded , placebo-controlled , sequential SAD study male and/or female type 2 diabetes mellitus patient . Part C randomize , double-blinded , placebo-controlled , 14-day multiple ascend dose ( MAD ) study healthy male and/or female subject . Subjects receive sequential dos DM-199 placebo sc 14 day . Part D randomize , double-blinded , placebo-controlled , 28-day multiple-dose proof concept ( POC ) study male and/or female type 2 diabetes mellitus patient . Subjects receive parallel dos DM199 placebo sc 28 day . The primary objective evaluate safety tolerability single multiple subcutaneous dos DM199 healthy subject type 2 diabetes mellitus patient . Another objective determine plasma pharmacokinetic profile DM199 administration single multiple dos DM199 healthy subject type 2 diabetes mellitus patient . Secondary objective include determine effect DM199 glucose homeostasis ( via fast glucose HbA1c level ) , standardized meal tolerance test , C-peptide , fructosamine , GLP-1 ( active total ) , glucagon , adiponectin lipid measurement , homeostatic model assessment insulin resistance/beta cell function ( HOMA ) determination type 2 diabetes mellitus patient ; assess formation antibody DM199 administration multiple dose DM199 healthy subject type 2 diabetes mellitus patient ; determine change immune cell population fluorescence-activated cell sort analysis follow multiple dos DM199 healthy subject type 2 diabetes mellitus patient</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>1 . Status : Parts A C : healthy subject Parts B D : type 2 diabetes mellitus patient : 2 . Body Mass Index : Parts A C : 18.0 30.0 kg/m2 Parts B D : 25.0 35.0 kg/m2 3 . HbA1c : Parts B D : screen 6.5 % 9.0 % , inclusive patient use one oral antidiabetic medication , 6.0 % 8.5 % , inclusive patient use two oral antidiabetic medication 4 . Fasting blood glucose : Parts B D : within 7.513.5 mmol/L , inclusive entry clinical research center ( Day 1 Part B Day 2 Part D ) 5 . Women childbearing potential agree use appropriate contraceptive method ( hormonal , IUD , diaphragm ) 90 day followup visit . For male : willingness use adequate contraception entry clinical research center 90 day followup visit 6 . Medical history without clinically significant abnormality 7 . Parts B D : Taking stable dose one oral antidiabetic medication , metformin , sulphonylurea orally administer glucose lower medication ( except thiazolidinediones ) least 3 month prior screen . Receiving chronic medication , include dietary supplement , alter blood glucose control . 8 . Parts A C : Resting supine blood pressure 140/90 mmHg low high 90/50mmHg screening , show clinically relevant deviation judge Principal Investigator 9 . Parts B D : Resting supine blood pressure 160/100 mmHg low high 90/50mmHg screening , show clinically relevant deviation judge Principal Investigator 1 . Evidence clinically relevant pathology 2 . Pregnancy lactation 3 . For healthy volunteer : use concomitant medication , except acetaminophen ( paracetamol ) , allow 3 day entry clinical research center ( time use limited amount acetaminophen permit consultation Principal Investigator ) . Multivitamins vitamin C allow 7 day entry clinical research center . All medication ( include counter medication , health supplement , herbal remedy St. John 's Wort extract ) must stop least 14 day prior entry clinical research center . 4 . Participation drug study within 60 day prior drug administration . Participation 3 drug study ( men ) / 2 drug study ( woman ) 10 month precede start study ) 5 . Positive drug screen ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine , tricyclic antidepressant alcohol ) 6 . Intake 24 unit alcohol per week ( one unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 7 . Positive screen HBsAg , antiHCV antiHIV 1/2 8 . Illness within 7 day prior ( first ) drug administration 9 . Serum creatinine &gt; upper limit normal ( ULN ) range Additional Exclusion Criteria Specific Type 2 Diabetes Mellitus Patients ( Part B Part D ) 10 . The use insulin thiazolidinediones type 2 diabetes mellitus 3 month prior screen allow . 11 . The use angiotensin convert enzyme ( ACE ) inhibitor 1 month prior screen allow . 12 . History diabetic ketoacidosis hyperosmolar coma 13 . Advanced diabetic complication , include neuropathy , nephropathy , retinopathy symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>HbA1c</keyword>
	<keyword>blood glucose</keyword>
	<keyword>glucose control</keyword>
	<keyword>DiaMedica</keyword>
	<keyword>DM-199</keyword>
	<keyword>DM199</keyword>
	<keyword>recombinant human tissue kallikrein-1</keyword>
	<keyword>tissue kallikrein-1</keyword>
</DOC>